| 摘要 |
<p>The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R<SUP>1 </SUP>and R<SUP>2 </SUP>are independently from each other is selected from the group consisting of hydrogen or C<SUB>1</SUB>-C<SUB>6</SUB>-alkyl; R<SUP>4 </SUP>and R<SUP>5 </SUP>are each independently from each other selected from the group consisting of H, hydroxy, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, carboxy, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>1</SUB>-C<SUB>3 </SUB>alkyl carboxy, C<SUB>2</SUB>-C<SUB>3 </SUB>alkenyl carboxy, C<SUB>2</SUB>-C<SUB>3 </SUB>alkynyl carboxy, amino or R<SUP>4 </SUP>and R<SUP>5 </SUP>may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<SUP>4 </SUP>or R<SUP>5 </SUP>is not a hydrogen or C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl</p> |
